|
Oxford BioMedica PLC - Oxford, England-based gene and cell therapy company - Says subsidiary Oxford Biomedica Solutions LLC has signed a deal with an unnamed new partner, for an undisclosed sum. Says the deal gives the US-based, private biotechnology firm access to Oxford BioMedica Solutions's process and manufacturing platform.
Chair & Interim Chief Executive Officer Roch Doliveux says: ‘This agreement marks a very important step towards achieving our strategic objective of becoming a global viral vector leader across all key vector types, delivering life changing therapies to patients.’
Under the pact, Oxford Biomedica Solutions, a high-performing full-scope adeno-associated virus manufacturing and innovation business, will receive payments relating to the full scope of process development.
Adenoviruses are a group of widely-studied viruses that are not known to cause disease and could be used for gene therapy.
Current stock price: 458.69 pence, up 1.3%
12-month change: down 69%
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
